Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sanofi (SNY) Enterprise Value (2016 - 2026)

Sanofi's Enterprise Value history spans 18 years, with the latest figure at -$6.9 billion for Q1 2026.

  • On a quarterly basis, Enterprise Value rose 11.44% to -$6.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.9 billion, a 11.44% increase, with the full-year FY2025 number at -$8.3 billion, down 10.1% from a year prior.
  • Enterprise Value hit -$6.9 billion in Q1 2026 for Sanofi, up from -$8.3 billion in the prior quarter.
  • Over the last five years, Enterprise Value for SNY hit a ceiling of -$6.9 billion in Q1 2023 and a floor of -$13.8 billion in Q2 2023.
  • Historically, Enterprise Value has averaged -$9.1 billion across 5 years, with a median of -$8.5 billion in 2024.
  • The widest YoY moves for Enterprise Value: up 38.34% in 2023, down 29.12% in 2023.
  • Tracing SNY's Enterprise Value over 5 years: stood at -$12.9 billion in 2022, then rose by 29.85% to -$9.0 billion in 2023, then increased by 16.13% to -$7.6 billion in 2024, then dropped by 10.1% to -$8.3 billion in 2025, then grew by 16.91% to -$6.9 billion in 2026.
  • Business Quant data shows Enterprise Value for SNY at -$6.9 billion in Q1 2026, -$8.3 billion in Q4 2025, and -$8.7 billion in Q3 2025.